Sun Pharmaceutical Industries reported a 27 per cent year-on-year increase in consolidated net profit to 2,894.7 crore for Q1FY27, with revenue growing 10 per cent to 15,299.8 crore, driven by strong performance in India and innovative medicines.
Indian pharmaceutical companies are not rushing to relocate manufacturing to the United States despite former President Donald Trump's renewed threat of tariffs up to 200 per cent on imported generic drugs. Instead, they are leveraging existing US plants, contract manufacturers, and making selective investments in complex products while maintaining India as their primary production hub.
Sun Pharmaceutical Industries Ltd has announced its acquisition of US-based Organon & Co in an all-cash deal valued at an enterprise valuation of USD 11.75 billion, aiming to become a top 25 global pharmaceutical company.
Rockwell Automation's CEO Blake Moret highlights India as the centrepiece of the company's Asian growth strategy, detailing its four-decade presence, significant employee base, and support for the 'Make in India' initiative. The company sees major opportunities in pharmaceuticals, automotive, food and beverage, and consumer products, with AI playing a crucial role in simplifying industrial automation and boosting productivity for Indian manufacturers, including MSMEs.
Indian companies' overseas expansion plans are holding strong despite geopolitical tensions in West Asia, driven by structural factors like supply-chain diversification, free trade agreements, and market expansion, according to Ajay Sharma, managing director and head of banking at HSBC India.
Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios.
'While salary increments are moderating compared to last year, not all functions are moving at the same pace.'
rediffGURU Nayagam PP advises young aspirants how to pick the right course and career.
'While higher prices may create some financial burden for patients and caregivers in the short term, uninterrupted access to treatment remains the greater priority.'
A Parliamentary Standing Committee on Commerce has urged the Indian government to swiftly conclude the proposed India-US Bilateral Trade Agreement (BTA), while ensuring India's interests are protected, recommending complete exemption for key export products like generic medicines and smartphones from future US tariff increases.
Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.
The Indian banking sector is projected to experience a steady 9-13 per cent industrial credit growth in the first half of 2026, driven by capital expenditure, infrastructure development, and sectoral demand recovery, according to a Ficci-IBA survey.
BikeWo Green Tech and Kwik Flite Support have signed an initial pact to develop an integrated air cargo, aviation logistics, and multimodal freight platform. This collaboration aims to combine road mobility with aviation capabilities to serve various industries, focusing on high-value and time-sensitive logistics across India, including Tier-II and Tier-III cities.
India's pharmaceutical industry is experiencing increased bulk drug prices, particularly for APIs from China, following the escalation of the West Asia crisis in March. While current inventories provide a temporary buffer, concerns are mounting over the availability of key solvents and feedstocks, potentially leading to manufacturing disruptions and shortages in specific drug categories.
'The market is currently neither cheap enough to be exciting about nor expensive enough to worry about.'
Indian benchmark stock indices Sensex and Nifty rebounded nearly 1 per cent, snapping a three-day decline, driven by rallies in Reliance Industries and Sun Pharma, alongside positive global market trends and easing geopolitical tensions.
Indian pharmaceutical companies are strategically increasing investments in the US market, focusing on specialty drugs, complex generics, respiratory products, and local manufacturing, despite a nearly 10 per cent fall in exports to the US in FY26 due to pricing pressure and competition in traditional generics.
The remarkable rise of smallcaps reflects the emergence of a broad set of specialised businesses operating in industries where the sectoral tailwinds remain considerably stronger than macroeconomic headwinds, points out Debashis Basu.
Specialty chemicals maker Anupam Rasayan India Ltd has become the first company globally to commercialise Ethyl trifluoroacetate (ETFA) production using its proprietary continuous flow chemistry platform. This innovative technology offers significant advantages over traditional methods, and ETFA is a crucial component for pharmaceuticals, life sciences, and performance materials, with a global market estimated at USD 500-600 million.
Corporate India is projected to offer salary increments ranging from 8.6 per cent to 10.2 per cent across various industries in the financial year 2026-27, primarily fuelled by a sustained demand for skilled and execution-focused talent, according to a TeamLease Services report.
Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.
The move follows reports from several state drug-regulatory authorities indicating misuse and hoarding oral formulations with high ethyl-alcohol concentration, which people use as a substitute for liquor.
Beijing clearly intends to extend the China-Myanmar Economic Corridor to Bangladesh as part of its larger Maritime Belt and Road Initiative to boost its Indian Ocean presence.
Indian foreign direct investment (FDI) in the United States has reached approximately USD 16.4 billion, supporting around 70,800 jobs and contributing significantly to research and development, according to US Deputy Undersecretary Brandon Remington.
Bharti Airtel added 7.64 trillion in value over the past five years, making it the biggest wealth creator in India's private sector, while the IT sector, including TCS, Infosys, and Wipro, collectively lost 8.5 trillion in value, according to the latest Burgundy Private Hurun India 500 report.
Notwithstanding the economic complementarities and the host of agreements for deepening economic relation on a host of areas, both sides share common viewpoints on the foreign policy domain and seek common grounds to serve as a counterweight to China, notes Dr Rajaram Panda.
Hyderabad-based SETL, a precision engineering company, has acquired a 51% majority stake in GScale Energy Private Limited, an AI Datacenter Engineering infrastructure specialist. This strategic move involves an initial investment of Rs 190 crore, with a total commitment of Rs 500 crore, marking SETL's expansion into the rapidly growing AI Datacenter sector and leveraging its expertise from pharmaceutical and chemical industries.
India's procurement of Venezuelan crude oil has picked up momentum since April and the South American nation has already emerged as the third largest oil supplier to the country.
'They talked bad about our leaders. They said India was a dead economy. They were not sensitive to the Indian psyche.'
A potential US-Iran peace deal, expected to be signed on June 19, is anticipated to ease geopolitical stress and benefit various sectors, particularly in India, with analysts suggesting investors await finer details before making significant moves.
Sun Pharmaceutical Industries' Executive Chairman Dilip Shanghvi described the USD 11.75 billion acquisition of US-based Organon & Co as both a "happy" and "bit anxious" moment, acknowledging the significant debt required to fund the large transaction.
The launch highlights the growing maturity of India's nuclear medicine ecosystem.
American industry groups sought punitive tariffs on Indian goods at USTR hearings, while Indian officials defended the country's manufacturing growth as demand-led and WTO-compliant.
Companies are already diversifying sourcing, raising prices, and reworking operating models as the disruption drags on.
Finance Minister Nirmala Sitharaman on Sunday proposed Rs 10,000 crore investment in the biopharma sector over the next five years, a move which would give a boost to the country's pharmaceuticals industry.
Karan Adani of Adani Ports & Special Economic Zone emerged as the top absolute value creator, adding Rs 2.67 trillion as the company's mcap rose from Rs 42,149 crore in March 2020 to Rs 3.09 trillion in March 2026 (7.3x) -- the largest rupee addition on the list.
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
Prime Minister Narendra Modi announced that the India-UK Comprehensive Economic and Trade Agreement (CETA) will come into effect on July 15, 2026, anticipating a significant boost to bilateral trade and investment.
Two former employees of a Delhi-based pharmaceutical firm have been booked for allegedly cheating, forging documents and impersonating to secure government tenders, including supplies to Army hospitals.
A recently finalised peace deal between the US and Iran, set to be signed on June 19, is expected to significantly benefit India's economy by boosting exports to West Asia, stabilising the rupee, and easing inflationary pressures, according to exporters and experts.
